SynBiotic Future Growth
Future criteria checks 2/6
SynBiotic is forecast to grow earnings and revenue by 134.2% and 33.8% per annum respectively. EPS is expected to grow by 136% per annum. Return on equity is forecast to be -1.3% in 3 years.
Key information
134.2%
Earnings growth rate
136.0%
EPS growth rate
Pharmaceuticals earnings growth | 20.7% |
Revenue growth rate | 33.8% |
Future return on equity | -1.3% |
Analyst coverage | Low |
Last updated | 12 May 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 17 | 0 | -3 | 1 | 1 |
12/31/2023 | 14 | -2 | -4 | 0 | 1 |
12/31/2022 | 8 | -24 | -7 | -7 | N/A |
12/31/2021 | 9 | -13 | -6 | -5 | N/A |
12/31/2020 | 5 | -1 | -3 | -1 | N/A |
12/31/2019 | N/A | 0 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SBX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SBX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SBX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SBX's revenue (33.8% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: SBX's revenue (33.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SBX is forecast to be unprofitable in 3 years.